Similarly, a retrospective analysis of cfDNA from a Chinese cohort of EGFRM+ NSCLC cases before treatment with 1G EGFR-TKIs detected co-existing mutations in EGFR or other cancer-relevant genes in 22% and 55% of patients, respectively, and showed that these co-alterations correlated with poor OR and OS after implementing these drugs [52]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.